Ming-Lin Li, Han-Yong Luo, Zi-Wei Quan, Le-Tian Huang, Jia-He Wang
{"title":"Prognostic and clinicopathologic significance of PLIN2 in cancers: A systematic review with meta-analysis.","authors":"Ming-Lin Li, Han-Yong Luo, Zi-Wei Quan, Le-Tian Huang, Jia-He Wang","doi":"10.1177/03936155221147536","DOIUrl":"https://doi.org/10.1177/03936155221147536","url":null,"abstract":"<p><p>The relationship between PLIN2 expression and prognosis, and clinicopathological significance of various cancers has been extensively studied, but the results are not completely consistent. This review followed the guidelines for systematic reviews of prognostic factors studies and was reported under the Preferred Reporting Program for Systematic Reviews and Meta-Analysis (PRISMA). We searched PubMed, Embase, Cochrane Library, Web of Science, and Google Academia for relevant articles up to September 2, 2022, and calculated the pooled hazard ratios (HR) with 95% confidence intervals (CI) to determine the association between PLIN2 expression and the prognosis of various cancers. The meta-analysis ultimately included 17 studies. The quality of all included cohort studies was evaluated using the Quality in Prognosis Studies (QUIPS) tool, and an adaptation of Grading of Recommendations Assessment, Development and Evaluation (GRADE) method was used to assess the certainty of the results. High expression of PLIN2 was associated with poorer overall survival (HR = 1.65; 95% CI = 1.14, 2.38; <i>P</i> = 0.008), metastasis-free survival (HR = 1.48; 95% CI = 1.12, 1.94; <i>P</i> = 0.005), progression-free survival (HR = 2.11; 95% CI = 1.55, 2.87; <i>P</i> < 0.0005) and recurrence-free survival/relapse-free survival (HR = 2.21; 95% CI = 1.64, 2.98; <i>P</i> < 0.0005) in cancers. The clinicopathological parameters of digestive system malignancies suggested that high expression of PLIN2 was notably associated with distant metastasis ( + ) (odds ratio (OR) = 3.37; 95% CI = 1.31, 8.67; <i>P</i> = 0.012), lymph node metastasis ( + ) (OR = 1.61; 95% CI = 1.01, 2.54; <i>P</i> = 0.004), and tumor stage (III-IV) (OR = 1.96; 95% CI = 1.24, 3.09; <i>P</i> = 0.006). In summary, overexpression of PLIN2 is significantly associated with a poor prognosis in various human cancers, especially in respiratory and digestive malignancies. Thus, PLIN2 expression may be a potential prognostic biomarker in cancer patients.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9230897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Esraa Al-Khateeb, Manal A Abbas, Majd B Khader, Maher A Sughayer
{"title":"Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis.","authors":"Esraa Al-Khateeb, Manal A Abbas, Majd B Khader, Maher A Sughayer","doi":"10.1177/03936155221149749","DOIUrl":"https://doi.org/10.1177/03936155221149749","url":null,"abstract":"<p><strong>Background: </strong>Programmed death-ligand 1 (PD-L1) expression in some tumors has prognostic implications. This work aims at investigating PD-L1 expression in diffuse large B-cell lymphoma (DLBCL) and to study its association with clinicopathological variables.</p><p><strong>Methods: </strong>The study consisted of 75 DLBCL patients who were cared for at the King Hussein Cancer Center during the period 2015-2018. The expression of PD-L1 in tumor tissue was assessed by immunohistochemistry using the anti-human PD-L1 (Clone 22C3) monoclonal antibody. The correlation between gender, age, clinical stage, pre-treatment-LDH level, tumor location, response to therapy, overall and event-free survival with PD-L1 expression was studied.</p><p><strong>Results: </strong>Six patients were excluded from further analysis as they were in relapse at the time of tissue sampling. The tumor proportion score (TPS) was ≥1% in 16/69 (23.2%) of DLBCL cases while the combined positive score (CPS) at a cut-off of ≥20 was observed in 23/69 (33.3%) cases. No significant difference in PD-L1 expression was found between germinal center B-cell-like (GCB) and non-GCB subtypes. Similarly, no differences in PD-L1 expression (at CPS ≥20 and TPS ≥1) were found between different genders, age groups, clinical stages, tumor location, and patient response to therapy. However, base-line lactate dehydrogenase was significantly elevated in patients with PD-L1 CPS ≥20. The overall survival was not significantly different between PD-L1-positive and -negative groups. On the other hand, the median event-free survival was higher in either of the PD-L1 TPS or CPS negative groups at 107months each versus 54 months in the PD-L1 positive group of either category.</p><p><strong>Conclusions: </strong>PD-L1 expression can predict event-free survival in DLBCL cases and therefore poor prognosis.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9237414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rosella Silvestrini, Ph.D., a pioneer in the field of translational research in oncology, passed on January 5, 2023, at the age of 92.","authors":"","doi":"10.1177/03936155231160685","DOIUrl":"https://doi.org/10.1177/03936155231160685","url":null,"abstract":"Born in 1930 in Faenza, Italy, Silvestrini graduated with highest honors from the University of Milan in 1952 with a Master of Science degree in biology, and acquired a teaching position in Normal and Pathological Immunohistochemistry in 1964. In the early days of her career, Rosella Silvestrini joined Farmitalia, the largest pharmaceutical company in Italy in the 1970s. Successively, from 1963, she spent much of her career at Milan’s Istituto Nazionale Tumori (National Cancer Institute), initially as a researcher of the National Research Council and later as Director of one of the five Divisions of Experimental Oncology. In 1997 she joined the Istituto Oncologico Romagnolo (Romagna Oncologic Institute) as a scientific consultant coordinator of the research laboratories. During her professional activity, she acted as an advisor in various scientific institutions, and has held positions in the Italian Ministry of University and Research and in the Ministry of Health (in commissions for national research and for oncology plans), and in the National Research Council Committees in which she collaborated in planning the three subsequent special Italian projects focused on oncology. Rosella Silvestrini started her distinguished career in the Farmitalia’s team of Aurelio Di Marco, where she contributed to the discovery and characterization of daunomycin, an antibiotic active against leukemia from which adriamycin was subsequently derived. These studies were conducted in close collaboration with the team of clinicians at the Istituto Nazionale Tumori of Milan, with the close and fruitful collaboration that made possible the development of effective treatments that significantly changed the natural history of solid and systemic malignancies, since then recognized and codified by the international scientific community. The strong collaboration with clinicians that characterized the beginning of Sivestrini’s activity primed and characterized the continuation of her career. Silvestrini led several groundbreaking studies on the biologic factors underlying cancer development, invasiveness, and progression and on determinants of sensitivity/ resistance to clinical treatments, to identify prognostic and predictive markers, and on the action mechanisms of chemical, physical and biological agents in experimental models to define optimal treatment schedules. She was one of the first investigators to report a link between tumor cell proliferation and breast cancer prognosis: in this context and with the support of various Italian cancer institutes, she contributed to the activation around 1990 prospective studies to evaluate the clinical utility of determining proliferation indices to identify patients with stage I tumors at high risk of disease recurrence who could benefit from adjuvant treatments. Furthermore, according to one key scientific question concerning the use of robust and reliable biomarkers in clinical trials, which should be measurable with little or ","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9239384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yingtian Zhang, Yaping Cheng, Liqiang Qin, Yuanliang Liu, Sijia Huang, Liya Dai, Jialong Tao, Jie Pan, Cunjin Su, Yusong Zhang
{"title":"Plasma metabolomics for the assessment of the progression of non-small cell lung cancer.","authors":"Yingtian Zhang, Yaping Cheng, Liqiang Qin, Yuanliang Liu, Sijia Huang, Liya Dai, Jialong Tao, Jie Pan, Cunjin Su, Yusong Zhang","doi":"10.1177/03936155221137359","DOIUrl":"https://doi.org/10.1177/03936155221137359","url":null,"abstract":"<p><strong>Objectives: </strong>Non-small cell lung cancer (NSCLC) is a leading type of lung cancer with a high mortality rate worldwide. Although many procedures for the diagnosis and prognosis assessment of lung cancer exist, they are often laborious, expensive, and invasive. This study aimed to develop an ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)-based analysis method for the plasma biomarkers of NSCLC with the potential to indicate the stages and progression of this malignancy conveniently and reliably.</p><p><strong>Methods: </strong>A total of 53 patients with NSCLC in early stages (I-III) and advanced stage (IV) were classified into the early and advanced groups based on the tumor node metastasis staging system. A comprehensive metabolomic analysis of plasma from patients with NSCLC was performed via UPLC-MS/MS. Principal component analysis and partial least squares-discriminant analysis were conducted for statistical analysis. Potential biomarkers were evaluated and screened through receiver operating characteristic analyses and correlation analysis. Main differential metabolic pathways were also identified by utilizing metaboanalyst.</p><p><strong>Results: </strong>A total of 129 differential metabolites were detected in accordance with the criteria of VIP ≥ 1 and a <i>P</i>-value of ≤ 0.05. The receiver operating characteristic curves indicated that 11 of these metabolites have the potential to be promising markers of disease progression. Apparent correlated metabolites were also filtered out. Furthermore, the 11 most predominant metabolic pathways with alterations involved in NSCLC were identified.</p><p><strong>Conclusion: </strong>Our study focused on the plasma metabolomic changes in patients with NSCLC. These changes may be used for the prediction of the stage and progression of NSCLC. Moreover, we discussed the metabolic pathways wherein the altered metabolites were mainly enriched.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9590728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic value of alkaline phosphatase and bone-specific alkaline phosphatase in breast cancer: A systematic review and meta-analysis.","authors":"Chengying Jiang, Fangke Hu, Xiaoqing Xia, Xiaojing Guo","doi":"10.1177/03936155231154662","DOIUrl":"https://doi.org/10.1177/03936155231154662","url":null,"abstract":"<p><p>Numerous studies have reported the clinical value of alkaline phosphatase (ALP) and its bone-specific isoforms (bone-specific alkaline phosphatase (BAP)) in breast cancer. The purpose of this meta-analysis was to summarize the prognostic value of serum ALP and BAP in breast cancer, especially focused on bone metastasis and survival. PRISMA guidelines were followed to conduct this review. Observational studies were searched in PubMed, Cochcrane Library and EMBASE to January 1, 2022. Data were extracted to explore the prognostic value of ALP and BAP. The quality of the included studies was assessed and the outcome effects were evaluated. Subgroup and sensitivity analyses were performed to explore the potential sources of heterogeneity. Publication bias was assessed. There was a total of 53 studies with 22,436 patients included. For the primary outcome of survival, high levels of both ALP and BAP were associated with short survival time. The hazard ratio of high ALP level on overall survival was 1.72 (95% CI 1.37, 2.16, <i>P</i> < 0.001). For the secondary outcomes, a high ALP level (not BAP) was detected in breast cancer compared with healthy controls, and high levels of both ALP and BAP were risk factors for bone metastasis, while ALP (not BAP) was a risk factor for non-bone metastasis. This study showed that high levels of both serum ALP and BAP were associated with metastasis (BAP was associated with bone metastasis) and survival in breast cancer. The biomarkers could provide useful information for the early diagnostic assessment and monitoring in the follow-up of breast cancer patients.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9238107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diagnostic and prognostic values of MMP-9 expression in ovarian cancer: A study based on bioinformatics analysis and meta-analysis.","authors":"Changyu Liu, Ying Shen, Qiyan Tan","doi":"10.1177/03936155221140421","DOIUrl":"https://doi.org/10.1177/03936155221140421","url":null,"abstract":"<p><p>This study aims to explore the expression of matrix metalloproteinase-9 (MMP-9) associated with both diagnostic and prognostic value in ovarian cancer by meta-analysis and bioinformatics analyses. We investigated the prognostic value of MMP-9 expression in ovarian cancer based on The Cancer Genome Atlas. Five databases were used to collect records about MMP-9 expression related to diagnostic and prognostic values in ovarian cancer from inception to June 2022. Using Stata 15.0 software, hazard ratio (HR) and odds ratio (OR) were calculated as the effect index of prognosis. We chose the pooled sensitivity, specificity, and area under the curve (AUC) to judge the diagnostic utility of MMP-9 for ovarian cancer. A total of 23 studies on prognosis, and five studies on diagnosis were entered into the meta-analysis. These suggest that high MMP-9 expression was detrimental to the overall survival of patients with ovarian cancer (HR = 1.34; 95% confidence interval (CI) 1.08∼1.66; <i>P<</i>0.01). High MMP-9 expression increased the risk of tumor stage (OR = 3.66; 95% CI 1.89∼7.07), but was not related to the tumor grade of ovarian cancer (<i>P></i>0.05). The pooled analysis of serum MMP-9 diagnosing for ovarian cancer gave the pooled sensitivity, specificity, and AUC the values of 0.72 (95% CI 0.61∼0.81), 0.81 (95% CI 0.77∼0.85), and 0.84 (95% CI 0.81∼0.87), respectively. High MMP-9 expression can increase the tumor stage, and a correlation exists between high MMP-9 expression and poor prognosis in patients with ovarian cancer. Also, serum MMP-9 has a good diagnostic value for ovarian cancer.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9291327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aleksandrs Krigers, Patrizia Moser, Helga Fritsch, Matthias Demetz, Johannes Kerschbaumer, Konstantin R Brawanski, Claudius Thomé, Christian F Freyschlag
{"title":"The relationship between connexin-43 expression and Ki67 in non-glial central nervous system tumors.","authors":"Aleksandrs Krigers, Patrizia Moser, Helga Fritsch, Matthias Demetz, Johannes Kerschbaumer, Konstantin R Brawanski, Claudius Thomé, Christian F Freyschlag","doi":"10.1177/03936155221143138","DOIUrl":"https://doi.org/10.1177/03936155221143138","url":null,"abstract":"<p><strong>Background: </strong>Advanced intercellular communication is a known oncogenic factor. In the central nervous system, Connexin-43 (Cx43) forms this junctional networking. Moreover, it correlates with the proliferation rate, and thus behavior, of gliomas. We assessed the expression of Cx43 and its relationship to Ki67 in other common central nervous system tumors.</p><p><strong>Methods: </strong>The expression of Cx43 and Ki67 were assessed in formalin-fixed paraffin embedded samples of human brain metastases, meningiomas, and neurinomas using immunohistochemistry. Neurinomas and meningiomas were jointly evaluated due to similar non-malignant behavior.</p><p><strong>Results: </strong>A total of 14 metastases of different extracerebral carcinomas, 6 meningiomas, and 10 neurinomas were evaluated. Five (36%) metastases and 5 (31%) meningiomas/neurinomas showed minor expression, whereas 6 (43%) metastases and 2 (13%) meningiomas/neurinomas showed no Cx43 expression at all. In 3 (21%) metastases and 9 (56%) meningiomas/neurinomas, moderate or strong expression of Cx43 was identified. The higher expression of Cx43 in meningiomas and neurinomas directly correlated with Ki67, r = 0.53 (<i>P</i> = 0.034). For metastases no significant correlation was found. Mitotic index in meningiomas/neurinomas correlated with Ki67 expression, r = 0.74 (<i>P</i> < 0.001), but did not show statistically significant correlation with Cx43 expression in these tumors.</p><p><strong>Conclusions: </strong>The expression of Cx43 as a marker of cell-to-cell networking exposed a significant correlation with the Ki67-defined proliferation index in case of primary central nervous system neuroectodermal neoplasms. However, it does not seem to play a comparable role in metastases with extracerebral origin.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9237927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Massimo Gion, Roberto De Gobbi, Manuel Zorzi, Giovanni Carretta, Luca Leonardi, Stefano Guzzinati, Chiara Trevisiol, Maurizio Cancian, Giulia Cardinali, Federica Michieletto, Ruggero Dittadi, Aline S C Fabricio, Massimo Rugge, Francesca Russo
{"title":"Overordering of tumor marker for outpatients revealed by performance indicators and the impact of a health policy intervention: An observational study using administrative records.","authors":"Massimo Gion, Roberto De Gobbi, Manuel Zorzi, Giovanni Carretta, Luca Leonardi, Stefano Guzzinati, Chiara Trevisiol, Maurizio Cancian, Giulia Cardinali, Federica Michieletto, Ruggero Dittadi, Aline S C Fabricio, Massimo Rugge, Francesca Russo","doi":"10.1177/03936155231154663","DOIUrl":"https://doi.org/10.1177/03936155231154663","url":null,"abstract":"<p><strong>Purpose: </strong>The overuse of laboratory tests contributes to impair health systems effectiveness, tumor markers (TMs) being a paradigmatic example. In the present study we applied indicators of TMs appropriateness developed from administrative datasets to appraise regionwide overordering in the clinical practice.</p><p><strong>Patients and methods: </strong>TMs ordered to outpatients in the Veneto Region over 6 years were obtained from the eletronic Outpatients' Records of Diagnostic and Therapeutic Procedures. TMs orders were examined as aggregated data or stratified according to disease codes, gender, age, and requests per patient. TMs recommended only for specific malignancies were examined using epidemiological data obtained from Veneto Tumor Registry.</p><p><strong>Results: </strong>A total of 5,821,251 TMs were ordered in 4,382,159 patients over 6 years. Overall, 3,252,389 (55.9%) TMs were ordered without appropriate disease codes (ranging from 77.0% for PSA to 17.5% for CA15.3). TM orders declined over 6 years (-13.4%), with a noticeable reduction of orders without appropriate disease codes (-21.3%). Orders decreased sharply from 2015 to 2016, after the enactment of a national Decree-Law aimed at improving appropriateness, and remained stable thereafter. However, the rate of inappropriate TMs requests still remained elevated (44.4%) in the last year of observation, with orders of TMs being much higher than expected on the basis of prevalence and incidence figures of specific malignancies.</p><p><strong>Conclusions: </strong>Indicators developed from administrative datasets were effective in assessing the overordering of TMs and the impact of interventions to improve appropriateness. The developed indicators could be considered for other diagnostic tests.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9238458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meng Zhang, Yi Feng, Changda Qu, Meizhu Meng, Wenmei Li, Meiying Ye, Sisi Li, Shaolei Li, Yuanyuan Ma, Nan Wu, Shuqin Jia
{"title":"Comparison of the somatic mutations between circulating tumor DNA and tissue DNA in Chinese patients with non-small cell lung cancer.","authors":"Meng Zhang, Yi Feng, Changda Qu, Meizhu Meng, Wenmei Li, Meiying Ye, Sisi Li, Shaolei Li, Yuanyuan Ma, Nan Wu, Shuqin Jia","doi":"10.1177/03936155221099036","DOIUrl":"https://doi.org/10.1177/03936155221099036","url":null,"abstract":"<p><strong>Background: </strong>Non-invasive liquid biopsies of circulating tumor DNA (ctDNA) is a rapidly growing field in the research of non-small cell lung cancer (NSCLC). In this study, factors affecting the concordance of mutations in paired plasma and tissue and the detection rate of ctDNA in real-world Chinese patients with NSCLC were identified.</p><p><strong>Methods: </strong>Peripheral blood and paired formalin-fixed paraffin-embedded tumor tissue samples from 125 NSCLC patients were collected and analyzed by sequencing 15 genes. Serological biomarkers were tested by immunoassay.</p><p><strong>Results: </strong>The overall concordance between tumor and plasma samples and the detection rate of somatic mutations in ctDNA was 69.2% and 78.4%, respectively. The concordance and detection rate raised with clinical stage were stage I: 14.3%, 14.3%; stage II: 53.3%, 60.0%; stage III: 71.4%, 78.1%; stage IV: 74.1%, 85.2%. With increased tumor diameter, the concordance and detection rate raised from 33.33% to 71.64% and 33.33% to 80.8%, respectively. For patients with partial response, stable disease, progressive disease, and who were treatment-naïve, the concordance and detection rates were 0.0%, 62.7%, 75.2, 73.6%, and 16.7%, 61.9%, 83.3%, 86.5%, respectively. Serological markers: CEA, CA125, NSE, and CYFRA21-1 were significantly higher for patients with detectable somatic alterations in ctDNA than in those who were ctDNA negative (17.08 ng/mL vs. 3.95 ng/mL, 21.63 U/mL vs. 18.27 U/mL, 17.68 U/mL vs. 14.14 U/mL, and 6.55 U/mL vs. 3.81 U/mL, respectively).</p><p><strong>Conclusion: </strong>Advanced-stage, treatment naïve or poor therapy outcome, and large tumor size were associated with a high concordance and detection rate. Patients with detectable mutations in ctDNA had a higher level of carcinoembryonic antigen, CA125, NSE, and CYFRA21-1.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40474651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Segrado, Adalberto Cavalleri, Alice Cantalupi, Luigi Mariani, Sonia Dagnino, Vittorio Krogh, Elisabetta Venturelli, Claudia Agnoli
{"title":"A software-assisted untargeted liquid chromatography-mass spectrometry method for lipidomic profiling of human plasma samples.","authors":"Francesco Segrado, Adalberto Cavalleri, Alice Cantalupi, Luigi Mariani, Sonia Dagnino, Vittorio Krogh, Elisabetta Venturelli, Claudia Agnoli","doi":"10.1177/03936155221132291","DOIUrl":"https://doi.org/10.1177/03936155221132291","url":null,"abstract":"<p><strong>Introduction: </strong>In this paper, an analytical pipeline designed for untargeted lipidomic profiling in human plasma is proposed. The analytical pipeline was developed for case-control studies nested in prospective cohorts.</p><p><strong>Methods: </strong>The procedure consisted of isopropanol protein precipitation followed by reverse phase liquid chromatography coupled to high resolution mass spectrometry and software-assisted data processing. The compounds are putatively annotated by matching experimental mass spectrometry data with spectral library data using LipidSearch software. The lipid profile of a pool of plasma samples from 10 healthy volunteers was detected in both positive and negative polarity modes. The impact of the chosen polarity on the number and quality of the lipid identification has been evaluated.</p><p><strong>Results: </strong>More than 1000 lipids from 12 different classes were detected, 1150 in positive mode and 273 in negative mode. Nearly half of them were unambiguously identified by the software in positive mode, and about one-third in negative mode. The method repeatability was assessed on the plasma pool samples by means of variance components analysis. The intra- and inter-assay precision was measured for 10 lipids chosen among the most abundant found within the different lipid classes. The intra-assay coefficients of variation ranged from 2.56% to 4.56% while intra- and inter-day coefficients of variance never exceeded the 15% benchmark adopted. The lipidomic profiles of the 10 healthy volunteers were also investigated.</p><p><strong>Discussion: </strong>This method detects a wide range of lipids and reports their degree of identification. It is particularly fit and well-designed for large case-control epidemiologic studies.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10842887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}